Mabion S.A. Logo

Mabion S.A.

Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.

MAB | WAR

Overview

Corporate Details

ISIN(s):
PLMBION00016 (+1 more)
LEI:
259400KG5JVQPPZL6X53
Country:
Poland
Address:
Konstantynów Łódzki GEN. MARIANA LANGIEWICZA 60, 95-050 Konstantynów Łódzki
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mabion S.A. is a biopharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services to pharmaceutical and biotech companies globally. The company specializes in the development, analytics, and manufacturing of complex biologic drugs. Mabion leverages advanced statistical methodologies, such as Design of Experiments (DoE), to optimize bioprocesses, enhance product quality, and ensure regulatory compliance. This data-driven approach supports accelerated development timelines and efficient, robust manufacturing for its partners, demonstrated through its involvement in large-scale production projects for biologics and vaccine components.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-17 14:10
Regulatory News Service
Załącznik 2_Strategia ESG Mabion S.A.
Polish 11.7 MB
2025-11-17 14:10
Regulatory News Service
Załącznik 1_Strategia Mabion S.A.
Polish 1.4 MB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
English 8.3 KB
2025-11-17 14:10
Management Discussion and Analysis
Przyjęcie Strategii Spółki Mabion S.A. na lata 2025 - 2030 oraz ujawnienie opóź…
Polish 8.8 KB
2025-10-24 20:35
Related Party Transaction
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (EN)
English 2.5 KB
2025-10-24 20:35
Capital/Financing Update
Zawarcie z Twiti Investments Ltd. umowy pożyczki - Content (PL)
Polish 2.4 KB
2025-10-08 15:16
Audit Report / Information
Informacja dotycząca stanowiska Zarządu i opinii Rady Nadzorczej Mabion S.A. od…
Polish 264.8 KB
2025-10-08 15:16
Interim Report
Raport Biegłego Rewidenta
Polish 497.9 KB
2025-10-08 15:16
Interim Report
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Polish 228.5 KB
2025-10-08 15:16
Management Discussion and Analysis
Mabion_Sprawozdanie Zarządu_1H2025
Polish 3.2 MB
2025-10-08 15:16
Interim Report
Mabion MSSF_1H2025
Polish 3.4 MB
2025-10-08 15:16
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Stanowisko Zarządu i opinia Rady Nadzorczej Mabion S.A. odnoszące się do odmowy…
Polish 368.1 KB
2025-10-08 14:27
Audit Report / Information
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (EN)
English 1.0 KB
2025-10-08 14:27
Report Publication Announcement
Uzupełnienie raportu okresowego Spółki za I półrocze 2025 roku - Content (PL)
Polish 784 bytes

Automate Your Workflow. Get a real-time feed of all Mabion S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mabion S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mabion S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ectin Research AB Logo
Clinical-stage biotech developing novel cancer treatments, focusing on metastatic bladder cancer.
Sweden
ECTIN B
Edesa Biotech, Inc. Logo
Develops treatments for inflammatory and immune diseases like Acute Respiratory Distress Syndrome.
United States of America
EDSA
Edgewise Therapeutics, Inc. Logo
Developing novel therapeutics for rare and serious muscle disorders.
United States of America
EWTX
Editas Medicine, Inc. Logo
Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.
United States of America
EDIT
Eevia Health Plc Logo
Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.
Finland
EEVIA
Egetis Therapeutics Logo
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
Sweden
EGTX
EIKEN CHEMICAL CO.,LTD. Logo
Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.
Japan
4549
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan
4523
Elanco Animal Health Inc Logo
Develops medicines, vaccines, and services to treat and prevent disease in pets and farm animals.
United States of America
ELAN
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America
ELDN

Talk to a Data Expert

Have a question? We'll get back to you promptly.